https://www.selleckchem.com/pr....oducts/TG100-115.htm
0001), inhibited microphthalmia transcription factor (MITF) and tyrosinase ( 0.05) expression and strongly down-regulated the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) signaling pathway more significantly than the control or trametinib group ( 0.0001). Low concentrations of celecoxib (IC in nM range) sufficed to exert antineoplastic capabilities and enhanced the therapeutic response of metastatic melanoma treated with trametinib. Low concentrations of celecoxib (IC50 in nM range) sufficed to exert antineoplas
Like
Comment
Share
